about
Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction.Survival in BRAF V600-mutant advanced melanoma treated with vemurafenibClinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanomaMelanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulationImproved survival with vemurafenib in melanoma with BRAF V600E mutationImmunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trialsCombination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapySingle-cell analysis tools for drug discovery and developmentAdaptive Immune Resistance: How Cancer Protects from Immune AttackAnti-CTLA4 monoclonal antibodies: the past and the future in clinical applicationSafety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label studyHMGB1 mediates endogenous TLR2 activation and brain tumor regressionCutaneous wound healing through paradoxical MAPK activation by BRAF inhibitors.Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitorsImpact of MET expression on outcome in BRAF(V600E/K) advanced melanoma.Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma.Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.Improved overall survival in melanoma with combined dabrafenib and trametinib.Inhibition of Mutated, Activated BRAF in Metastatic MelanomaSafety and Tumor Responses with Lambrolizumab (Anti–PD-1) in MelanomaHepatotoxicity with combination of vemurafenib and ipilimumabMelanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 201531st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part oneModulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanomaTumor Immunotherapy Directed at PD-1The state of melanoma: challenges and opportunitiesEmerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in OncologyA systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers".Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses.Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA.Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials.Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanomaMulticenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanomaMultifunctional T-cell analyses to study response and progression in adoptive cell transfer immunotherapyNatural killer T cells in advanced melanoma patients treated with tremelimumabCTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans.PD-1 Blockade Expands Intratumoral Memory T Cells.
P50
Q24315032-8E6AFF49-E1D2-471A-BEC4-C82A05F6A8A0Q24594790-E95D7DA9-BF77-4195-B96E-0EDB5F640B19Q24597152-C336E288-00B7-446C-B545-2E5340F5721BQ24629474-43495A3A-5272-495D-A738-1CF45950D39AQ24631953-5A3C1E30-8A43-4A86-BB80-81FCF8FB6380Q26765115-916BFD77-42F6-4BEB-A09F-461770DAC31CQ26769870-304F89CD-F3E7-44D8-9B1E-96C3BF2F4F4DQ26775754-D414E2A4-C9DA-4EEF-8988-D9D8C4FCDBEDQ26798448-48447A3C-B434-4DAC-88F6-9D03764366A1Q26858779-57A527DD-9ED1-4814-A45B-7594F5017A00Q27276774-5CFBD8CB-E740-460E-BF42-E9D69FF7E4D0Q27307459-949ABBCA-7D88-41DC-A4E7-67629FA9142AQ27333987-89C32CF6-0036-41CC-944E-C81C94F63665Q27777363-51B3F9C0-000C-44E3-BD5E-46B757830ECBQ27851698-5C01C32A-2C00-4066-9948-30B58B1B0FE4Q27851843-7F091CAC-C225-4F4F-8B54-EFDA0AC557DAQ27852389-1B043722-4E0E-4008-8229-CA65F8562A38Q27852894-97FF6F0C-43D3-4EA4-9682-CF0383DC6B0CQ27852994-DCEBDDD0-7CC2-486C-9728-997812FB0E34Q27853076-444C0A49-193C-461C-8442-FDCC15100E9DQ27853091-C6694E8D-0C69-406A-8643-25E58303203FQ27860458-6BC5EE2F-457B-41F5-B213-92F720855A44Q27860650-6175B802-A7BB-43BA-B270-61E8A9B28069Q28288255-377A02AD-EBC5-4B6A-BB5B-930E5DA7AB8AQ28553228-83C55DDD-C3B7-4FF9-88B2-A17F2FA60BB8Q28553703-C7772016-810E-4E16-9C86-9DEF9D696EC7Q28749278-71B17CF6-B4C2-412D-97BA-CF7D32C3AE38Q29031159-BDBEB14F-2ECB-44A0-966A-6DF07B88FD8AQ30276971-CA38A88E-6FAC-44A8-A6B2-E61ED8B78A33Q30438965-4FD7C8B5-1B48-4D6D-A116-3A6D7FAB571AQ30440347-D46F18E2-5E57-45C6-AC95-DBD68156E831Q30496118-9BAB78BC-A7EC-4D3D-B4D3-BEBEFB70FEF5Q30837863-BCCCA867-E5BF-4D40-868F-50BDF076FC36Q31143336-86EF8C24-D697-479A-969D-10B8FBC46B45Q33806306-4630F3BD-95D2-4954-9398-4A506FEC8A8FQ34198563-0DA6DE5D-AFE4-4779-9B1C-D4C86640E1C6Q34334598-DE48FBEA-EF9A-4AB3-B701-0EFF0DE11093Q35027661-41165F26-10EE-4C6F-9020-FBBA5703B4A5Q35053486-42C97EC2-D37A-4EBE-ADA4-5E06C32234F7Q36642804-9C9EC6B7-41BB-4939-9609-1EE8746A2A64
P50
description
onderzoeker
@nl
name
Antoni Ribas
@en
Antoni Ribas
@es
type
label
Antoni Ribas
@en
Antoni Ribas
@es
prefLabel
Antoni Ribas
@en
Antoni Ribas
@es